Abstract

A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2

Author(s): Gillson George R, Zava David T

Issue: Sep/Oct 2003 - After the Women's Health Initiative Trial

Page(s): 330-338

Download in electronic PDF format for $75
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 1
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 2
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 3
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 4
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 5
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 6
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 7
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 8
  • A Perspective on HRT for Women: Picking Up the Pieces After the Women's Health Initiative Trial - Part 2 Page 9

Abstract

This second part of a two-part series focuses on a discussion of progesterone and progestins differentiating the two in terms of synergy between estradiol and progesterone, balance between estrone and estrogen sulfate within tumor cells, protection of the uterine linings and impact on cardiovascular function; and bioidentical progesterones (oral and topical). Sidebars provide examples of studies showing adverse effects of medroxyprogesterone acetate on cardiovascular health, progesterone’s beneficial effects on cardiovascular function, results with bioidentical progesterone, results with topical progesterone and a protocol for combined hormone replacement therapy using progesterone skin cream. The authors conclude that physicians should not turn their backs on patients suffering from hormonal deficiencies in the absence of large clinical trials with bioidentical hormones since the literature suggests estradiol and estriol would be good estrogens to use and transdermal delivery of hormones is advantageous over oral delivery. With oral delivery, doctors should rethink dosing and consider impact on other relevant parameters. It appears that certain progestins should be avoided in favor of bioidentical progesterone, and saliva testing can allow monitoring of hormone levels. With good follow-up, clinical judgment and laboratory backup, there is enough information about hormone replacement to offer bioidentical hormone replacement therapy as a viable option. A patient handout on hormone replacement therapy accompanies the article.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Sep/Oct 2003
Pg. 330-338
Jan/Feb 2004
Pg. 16-21
Jul/Aug 2003
Pg. 250-256
Jan/Feb 2004
Pg. 10-14
Author(s): Preckshot John
Mar/Apr 2004
Pg. 96-99
Sep/Oct 2016
Pg. 359-364
Author(s): Deleruyelle Laura J
Nov/Dec 2016
Pg. 447-454
Author(s): Deleruyelle Laura J
Jan/Feb 2013
Pg. 74-85
View Sample
Mar/Apr 2010
Pg. 165-170
Jan/Feb 2017
Pg. 6-16
Author(s): Deleruyelle Laura J
Nov/Dec 2020
Pg. 466-470
Author(s): DeRosa Angela
Jul/Aug 2008
Pg. 295-304
Jan/Feb 2001
Pg. 52-54
Author(s): Ford Gina, Garcia Lea
Jul/Aug 2007
Pg. 292-296
Jan/Feb 2014
Pg. 70-77
Nov/Dec 2004
Pg. 427-435
Author(s): Stephenson Kenna
Jan/Feb 2021
Pg. 14-17
Author(s): DeRosa Angela
Jan/Feb 2002
Pg. 50-54
Author(s): Wepfer Scott T
Mar/Apr 2002
Pg. 142-146
Author(s): Wepfer Scott T
Jul/Aug 2002
Pg. 255-256
Author(s): Mason Dave